


PHARMACEUTICAL 2022



ORAMED







PHARMACEUTICAL 2022

ORAMED PHARMACEUTICALS INC. Rank 30 of 475



The relative strengths and weaknesses of ORAMED PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ORAMED PHARMACEUTICALS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 161% points. The greatest weakness of ORAMED PHARMACEUTICALS INC. is the variable Revenues, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 458% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	95,337
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,679
Liabilities, Non-Current	4,803
Other Assets	32,265
Other Compr. Net Income	45,227
Other Expenses	8.0
Other Liabilities	0
Other Net Income	1,242
Property and Equipment	397
Research and Development	20,989
Revenues	2,703
Selling, General and Administrative Expense	5,937

Output Variable	Value in 1000 USD
Assets	127,999
Liabilities	11,482
Expenses	26,934
Stockholders Equity	116,517
Net Income	-22,989
Comprehensive Net Income	-376
Economic Capital Ratio	182%

